Physician profile
Aaron Tauer
NPI 1992185094
$2,594.09
in general payments reported to CMS, 2019-2025
20 companies · $873 in 2025
The $873 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2023: $541 · 2024: $774 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,103.71 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $525.86 | 2023-2025 | Ubrelvy, Qulipta |
| Eisai INC. | $271.29 | 2023-2025 | |
| Ucb, INC. | $260.87 | 2019-2025 | Fintepla, Briviact, Nayzilam |
| Neurelis, INC. | $225.40 | 2023-2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $216.70 | 2023-2024 | Xeomin |
| Acadia Pharmaceuticals INC | $162.86 | 2023-2025 | Nuplazid, Daybue |
| Genzyme Corporation | $159.90 | 2019 | |
| Emd Serono, INC. | $153.74 | 2019 | |
| Tg Therapeutics, INC. | $116.16 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $101.20 | 2023 | Soliris |
| Sk Life Science, INC. | $80.04 | 2025 | Xcopri |
| Pfizer INC. | $70.58 | 2023-2025 | |
| Biogen, INC. | $59.79 | 2023-2025 | Tysabri, Vumerity, Leqembi |
| Jazz Pharmaceuticals INC. | $49.77 | 2024-2025 | |
| Neuropace, INC. | $48.93 | 2024-2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $25.06 | 2023 | |
| Celgene Corporation | $22.22 | 2023 | Zeposia |
| Gt Medical Technologies, INC | $16.93 | 2023 | Gammatile |
| Nevro Corp. | $13.44 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $13.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Tauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.